MET and cancer: In our cohort, we identified a case that carried the G719C/S768I combination and somehow surprisingly showed OR to erlotinib, considering that it also harbored MET-amplification, MET-overexpression, and mutated TP53. Similarly, Hong et al. observed PR to erlotinib in patients, whose EGFRM+ NSCLC harbored G719X or L861Q together with co-mutations in other cancer-driver genes [52].